CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

TitleCCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Publication TypeJournal Article
Year of Publication2016
AuthorsHenrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DR
JournalJ Infect Dis
Volume213
Issue5
Pagination766-70
Date Published2016 Mar 1
ISSN1537-6613
KeywordsAnti-HIV Agents, Case-Control Studies, DNA, Circular, DNA, Viral, Female, Genetic Predisposition to Disease, HIV Infections, HIV-1, Humans, Lymphocyte Activation, Male, Receptors, CCR5, RNA, Viral, T-Lymphocytes
Abstract

We conducted a case-controlled study of the associations of CCR5-Δ32 heterozygosity with human immunodeficiency virus type 1 (HIV-1) reservoir size, lymphocyte activation, and CCR5 expression in 114 CCR5(Δ32/WT) and 177 wild-type CCR5 AIDS Clinical Trials Group participants receiving suppressive antiretroviral therapy. Overall, no significant differences were found between groups for any of these parameters. However, higher levels of CCR5 expression correlated with lower amounts of cell-associated HIV-1 RNA. The relationship between CCR5-Δ32 heterozygosity, CCR5 expression, and markers of HIV-1 persistence is likely to be complex and may be influenced by factors such as the duration of ART.

DOI10.1093/infdis/jiv504
Alternate JournalJ. Infect. Dis.
PubMed ID26512140
PubMed Central IDPMC4747624
Grant List1K23AI098480-01A1 / AI / NIAID NIH HHS / United States
K23 AI098480 / AI / NIAID NIH HHS / United States
P30 AI060354 / AI / NIAID NIH HHS / United States
R37 AI055357 / AI / NIAID NIH HHS / United States
U01AI068636 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI106701 / AI / NIAID NIH HHS / United States